NYSE
Core Laboratories Inc. (CLB)
♥ 284 Thanks from members
Core Laboratories Inc. (CLB) exhibits a neutral to cautious market consensus, driven by Q2 2026 earnings beating EPS estimates despite geopolitical disruptions, though weighed down by low profit margins, a 39% six-month stock decline, and compressed free cash flow yields.